Review





Similar Products

96
Innovative Research Inc unprocessed human plasma uhpp
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Unprocessed Human Plasma Uhpp, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/unprocessed human plasma uhpp/product/Innovative Research Inc
Average 96 stars, based on 1 article reviews
unprocessed human plasma uhpp - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

92
Miltenyi Biotec plasma cell isolation kit ii
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Plasma Cell Isolation Kit Ii, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasma cell isolation kit ii/product/Miltenyi Biotec
Average 92 stars, based on 1 article reviews
plasma cell isolation kit ii - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

86
Sysmex Corporation human standard plasma
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Human Standard Plasma, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human standard plasma/product/Sysmex Corporation
Average 86 stars, based on 1 article reviews
human standard plasma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Kainos Laboratories human plasma by elisa
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Human Plasma By Elisa, supplied by Kainos Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human plasma by elisa/product/Kainos Laboratories
Average 86 stars, based on 1 article reviews
human plasma by elisa - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Shanghai Medicilon human plasma
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Human Plasma, supplied by Shanghai Medicilon, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human plasma/product/Shanghai Medicilon
Average 86 stars, based on 1 article reviews
human plasma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Siemens Healthineers standard human plasma
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Standard Human Plasma, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/standard human plasma/product/Siemens Healthineers
Average 86 stars, based on 1 article reviews
standard human plasma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

93
Innovative Research Inc heat inactivated human blood type ab serum
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Heat Inactivated Human Blood Type Ab Serum, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heat inactivated human blood type ab serum/product/Innovative Research Inc
Average 93 stars, based on 1 article reviews
heat inactivated human blood type ab serum - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

86
Biopredic human heparin na plasma
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Human Heparin Na Plasma, supplied by Biopredic, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human heparin na plasma/product/Biopredic
Average 86 stars, based on 1 article reviews
human heparin na plasma - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

94
Innovative Research Inc human plasma
Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
Human Plasma, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human plasma/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
human plasma - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

Image Search Results


Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

Journal: bioRxiv

Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

doi: 10.64898/2026.04.29.721601

Figure Lengend Snippet: Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

Techniques: Isolation, BIA-KA, Western Blot, Concentration Assay, Acid Assay, Size-exclusion Chromatography, Transmission Assay, Electron Microscopy, Clinical Proteomics

Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

Journal: bioRxiv

Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

doi: 10.64898/2026.04.29.721601

Figure Lengend Snippet: Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

Techniques: Flow Cytometry, Isolation, Labeling, Imaging, Fluorescence, Size-exclusion Chromatography, Clinical Proteomics